The emergence of a new variant of the seasonal influenza A(H3N2) virus has reignited debate around what the media has labeled the «super flu». This comes amid an unusually early rise in flu-like illnesses in several countries, including Morocco. In this interview, Dr. Tayeb Hamdi, physician and researcher in health policy and systems, addresses key questions about the nature of this variant, its risks, vaccine effectiveness, and recommended preventive measures. DR ‹ › What is the new influenza strain that has emerged, and why is it being described as a «super flu»? What risks does it pose? A new strain of influenza, referred to in the media and on social media as the «subclade K» or «super flu», has recently appeared and is spreading rapidly. It is a mutated form of the seasonal influenza A(H3N2) virus that acquired seven new mutations during the summer of 2025, making it notably different from the strain that circulated previously. These mutations have helped the virus partially escape existing immunity, leading to intense transmission among teenagers, young adults, and adults, and then among children and the broader population. Early flu waves were first reported in Japan, followed by the United States, Canada, Europe, and other countries. This rapid spread increases the overall virulence associated with the H3N2 strain, which is already known to be more aggressive than H1N1. In Morocco, cases seem to be rising. How do you assess the current epidemiological situation? Should we be concerned? In Morocco, pending official figures from the Ministry of Health, we are indeed seeing a noticeable increase in flu-like illnesses since mid-November, with cases rising more sharply in recent days than is typical for this time of year. As in other countries, we expect a higher number of infections, more severe cases, and increased complications among high-risk groups (people over 65, individuals with chronic illnesses, pregnant women, people with obesity or weakened immune systems, and children aged 6 months to 5 years). We also anticipate pressure on the healthcare system in the coming weeks, along with higher absenteeism in schools and workplaces. However, at this stage, there is no cause for alarm, and no extraordinary measures are anticipated. The priority remains prevention and encouraging people to take the necessary precautions. What are the symptoms? And what should someone do if they develop them? Symptoms caused by this new variant are similar to those of typical seasonal flu: high fever (39–40°C), chills, headache, runny nose, joint and muscle pain, dry cough, and sometimes diarrhea or vomiting. If symptoms appear, we recommend staying home, minimizing contact with others, especially high-risk individuals, practicing regular hand hygiene, ventilating indoor spaces, keeping sick children out of school, and wearing a mask if interaction with others is necessary. Vaccination is strongly recommended for vulnerable groups and for healthcare workers to protect themselves, support the health system, and reduce severe cases. Do current vaccines provide protection against this new variant? Vaccines for the 2025–2026 season contain the previous H3N2 strain, not the newly emerged variant. However, early data from the UK suggest that current vaccines still offer partial protection against infection and, crucially, strong protection against severe illness. Although flu vaccination campaigns typically begin in late September or early October, it is still advisable, especially for high-risk groups, to get vaccinated as soon as possible. Protection develops about two weeks after receiving the shot. Seasonal flu vaccination remains the most effective prevention tool. Are there effective treatments for this type of influenza? There is no medication that eliminates the influenza virus itself; treatment focuses on relieving symptoms. In severe cases, doctors may prescribe antiviral medications, but they must be started within the first three days of symptoms. Antibiotics do not treat influenza because it is a viral infection. However, some high-risk individuals may develop secondary bacterial infections, known as bacterial superinfections, when the flu weakens the respiratory system. In such cases, antibiotics may be prescribed, not for the flu itself but for the accompanying bacterial infection. Self-medicating with antibiotics or sharing them with others is dangerous and strongly discouraged, as each case requires medical assessment.
